26-18-105.   Drug prior approval program.
(1)  A drug prior approval program approved or implemented by the board shall
meet the following conditions:
(a)  except as provided in Subsection (2), a drug may not be placed on prior
approval for other than medical reasons;
(b)  the board shall hold a public hearing at least 30 days prior to placing a
drug on prior approval;
(c)  notwithstanding the provisions of Section 52-4-202, the board shall
provide not less than 14 days' notice to the public before holding a public
hearing under Subsection (1)(b);
(d)  the board shall consider written and oral comments submitted by
interested parties prior to or during the hearing held in accordance with
Subsection (1)(b);
(e)  the board shall provide evidence that placing a drug class on prior
approval:
(i)  will not impede quality of recipient care; and
(ii)  that the drug class is subject to clinical abuse or misuse;
(f)  the board shall reconsider its decision to place a drug on prior
approval:
(i)  no later than nine months after any drug class is placed on prior
approval; and
(ii)  at a public hearing with notice as provided in Subsection (1)(b);
(g)  the program shall provide an approval or denial of a request for prior
approval:
(i)  by either:
(A)  fax;
(B)  telephone; or
(C)  electronic transmission;
(ii)  at least Monday through Friday, except for state holidays; and
(iii)  within 24 hours after receipt of the prior approval request;
(h)  the program shall provide for the dispensing of at least a 72-hour supply
of the drug on the prior approval program:
(i)  in an emergency situation; or
(ii)  on weekends or state holidays;
(i)  the program may be applied to allow acceptable medical use of a drug on
prior approval for appropriate off-label indications; and
(j)  before placing a drug class on the prior approval program, the board
shall:
(i)  determine that the requirements of Subsections (1)(a) through (i) have
been met; and
(ii)  by majority vote, place the drug class on prior approval.
(2)  The board may, only after complying with Subsections (1)(b) through (j),
consider the cost:
(a)  of a drug when placing a drug on the prior approval program; and
(b)  associated with including, or excluding a drug from the prior approval
process, including:
(i)  potential side effects associated with a drug; or
(ii)  potential hospitalizations or other complications that may occur as a
result of a drug's inclusion on the prior approval process.
